| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 04/21/2005 | US20050084926 Method for cell-free protein complete post-translational modification |
| 04/21/2005 | US20050084913 Tumor antigen for use as tool in diagnosis, prevention and treatment of cell proliferative disorders; immunotherapy |
| 04/21/2005 | US20050084900 Mammalian cell membrane proteins; related reagents |
| 04/21/2005 | US20050084899 Compositions and methods relating to breast specific genes and proteins |
| 04/21/2005 | US20050084898 Comparative fluorescence hybridization to nucleic acid arrays |
| 04/21/2005 | US20050084897 DNA encoding human vanilloid receptor VR3 |
| 04/21/2005 | US20050084891 Beta 1,4-N-acetylgalactosaminyl transferases from C. jejuni |
| 04/21/2005 | US20050084889 Preferential display |
| 04/21/2005 | US20050084885 Modified transcription factor protein for use as tool in prevention and treatment of cell proliferative disorder |
| 04/21/2005 | US20050084878 Method for isolating and cloning high molecular weight polynucleotide molecules from the environment |
| 04/21/2005 | US20050084876 Flip genes and flip proteins |
| 04/21/2005 | US20050084873 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 04/21/2005 | US20050084868 Generation of stabilized proteins by combinatorial consensus mutagenesis |
| 04/21/2005 | US20050084864 Using reporter protein expression as diagnostic indicator preferential protein activity; bioassay |
| 04/21/2005 | US20050084861 Methods of detecting modification of genetic material and monitoring processes thereof |
| 04/21/2005 | US20050084860 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 04/21/2005 | US20050084859 Herbicide metabolizing proteins; ferredoxins; methylation, dehydrogenation; kits |
| 04/21/2005 | US20050084857 Breast tumor antigen for use as tool in diagnosis prevention and treatment of mammary gland cell proliferative disorders; antitumor agents |
| 04/21/2005 | US20050084854 Viral probes for use as tools in sequencing and genotyping lymphadenopathy associated viral subtypes |
| 04/21/2005 | US20050084853 Nucleotide sequences coding actin binding protein for use as tool in identifying modulator for prevention and treatment of fungal infection; fungicides |
| 04/21/2005 | US20050084851 Classifying preferential nucleic acids via sequencing-by-synthesis; genotyping and sequence determination |
| 04/21/2005 | US20050084850 Stromal cell protein for use as tool in stimulating blood production in patients undergoing chemotherapy |
| 04/21/2005 | US20050084845 Immunoglobulin specific to hepatitis c viral envelope protein for use as tool prevention and treatment of viral diseases |
| 04/21/2005 | US20050084844 Genetic screen for bioactive peptides |
| 04/21/2005 | US20050084840 Method for screening drug for improving insulin resistance |
| 04/21/2005 | US20050084839 Method for selecting oocytes by using a response to LPA stimulation |
| 04/21/2005 | US20050084522 Cationic lipids for nuclei acid delivery |
| 04/21/2005 | US20050084513 Nanocoating for improving biocompatibility of medical implants |
| 04/21/2005 | US20050084503 Continuous cell line for the production of vaccines |
| 04/21/2005 | US20050084497 Immunogens; replication-defective; antibodies; host cells; kits |
| 04/21/2005 | US20050084495 Altering A B cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent |
| 04/21/2005 | US20050084480 Recombinant replication-defective adenovirus serotypes 11, 25, 34, 35, 48 and 49 as gene delivery vehicles for gene therapy; reduced drug resistance, increased effectiveness of vaccination |
| 04/21/2005 | US20050084456 Functionalized particles |
| 04/21/2005 | US20050082221 phytoremediation using various fern plants for removing contaminated substances such as arsenic, from sites containing polluted soils and waters and airborne substances such as those found with waste water, ground water, surface water |
| 04/21/2005 | DE10392358T5 Verfahren und System für die in Vivo-Analyse von Entwicklungsvorgängen A method and system for the in vivo analysis of developmental processes |
| 04/21/2005 | CA2852842A1 Method for producing scyllo-inositol |
| 04/21/2005 | CA2774930A1 Method for producing purified scyllo-inositol utilizing boric acid |
| 04/21/2005 | CA2761987A1 Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| 04/21/2005 | CA2578473A1 Peptide nucleic acid conjugates and uses thereof |
| 04/21/2005 | CA2550583A1 Modified cea /b7 vector |
| 04/21/2005 | CA2548787A1 Antibody composition specifically binding to ganglioside gm2 |
| 04/21/2005 | CA2546730A1 A method for the treatment of malignant diseases by inhibiting nucleolin |
| 04/21/2005 | CA2542860A1 Fluorescence indicator utilizing fret |
| 04/21/2005 | CA2542288A1 Chimeric promoter comprising hcmv major immediate early gene exons and a heterologous intron |
| 04/21/2005 | CA2542130A1 Cell genomically modified to produce polypeptides with an altered glycosylation pattern |
| 04/21/2005 | CA2542125A1 Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| 04/21/2005 | CA2542121A1 Genomically modified cell neutralized to serum-free system |
| 04/21/2005 | CA2542046A1 Fused protein composition |
| 04/21/2005 | CA2542042A1 Antibody composition specifically binding to il-5 receptor |
| 04/21/2005 | CA2542037A1 Composition of antibody capable of specifically binding ccr4 |
| 04/21/2005 | CA2542035A1 Process for producing antithrombin iii composition |
| 04/21/2005 | CA2541804A1 Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| 04/21/2005 | CA2541671A1 Bispecific antibody substituting for functional proteins |
| 04/21/2005 | CA2541464A1 Piscirickettsia salmonis antigens and use thereof |
| 04/21/2005 | CA2541380A1 Use of cell lines to produce active therapeutic proteins |
| 04/21/2005 | CA2541360A1 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| 04/21/2005 | CA2540884A1 C-terminally truncated interferon alpha variants |
| 04/21/2005 | CA2540199A1 Nucleotide sequences and polypeptides encoded thereby useful for producing transformed plants expressing lethal/nonviability genes |
| 04/21/2005 | CA2539999A1 Antibody compositions and methods |
| 04/21/2005 | CA2539907A1 A root-preferred maize promoter named crwaq81 |
| 04/21/2005 | CA2539693A1 Protease variants |
| 04/21/2005 | CA2539681A1 Nucleic acid molecules encoding novel human low-voltage activated calcium channel proteins, designated - alpha 1i-1 and alpha 1i-2, encoded proteins and methods of use thereof |
| 04/21/2005 | CA2539262A1 Promoter for the epidermis-specific transgenic expression in plants |
| 04/21/2005 | CA2538903A1 Isolated photoprotein mtclytin, and use thereof |
| 04/21/2005 | CA2537473A1 Cytokine involved in epithelial-mesenchymal transition |
| 04/21/2005 | CA2535982A1 Uses of interferons with altered spatial structure |
| 04/20/2005 | EP1524695A2 Affinity based self-assembly systems and devices for photonic and electronic applications |
| 04/20/2005 | EP1524321A1 Non-invasive detection of fetal genetic traits |
| 04/20/2005 | EP1524318A1 Genes and proteins for the biosynthesis of polyketides |
| 04/20/2005 | EP1524317A1 Methods for isolating nucleic acids |
| 04/20/2005 | EP1524316A2 Method of determining propensity of bacteria for dissolved oxygen instability |
| 04/20/2005 | EP1524275A2 Deimmunized binding molecules to CD3 |
| 04/20/2005 | EP1523992A1 Vaccine formulation against Gumboro disease |
| 04/20/2005 | EP1523678A2 Functional screening method involving protein translocation/redistribution |
| 04/20/2005 | EP1523582A2 Rapid, efiicient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 04/20/2005 | EP1523580A2 Detection of microorganisms |
| 04/20/2005 | EP1523578A1 Diagnosis of sepsis using mitochondrial nucleic acid assays |
| 04/20/2005 | EP1523577A2 Method for diagnosis of intestinal-type gastric tumors |
| 04/20/2005 | EP1523574A2 Modular recombinatorial display libraries |
| 04/20/2005 | EP1523573A2 Disease detection by digital protein truncation assays |
| 04/20/2005 | EP1523572A2 Pathogenicity poteins which can be used as targets for developing means for preventing and controlling bacterial infections |
| 04/20/2005 | EP1523571A2 Sgk and nedd used as diagnostic and therapeutic targets |
| 04/20/2005 | EP1523564A1 Methods for inducing targeted stimulation of meiotic recombination and kits for performing said methods |
| 04/20/2005 | EP1523563A2 Modified adenoviral fiber with ablated to cellular receptors |
| 04/20/2005 | EP1523561A1 Method for the production of transgenic plants with increased virus resistance by silencing vegetable dnaj-like proteins |
| 04/20/2005 | EP1523560A2 Modulating developmental pathways in plants |
| 04/20/2005 | EP1523559A1 Cell wall mutants for delivery of biologically active compounds |
| 04/20/2005 | EP1523558A1 Production of peptides and proteins by accumulation in plant endoplasmic reticulum-derived protein bodies |
| 04/20/2005 | EP1523557A2 Antigens encoded by alternative reading frame from pathogenic viruses |
| 04/20/2005 | EP1523556A1 Methods of treating conditions associated with an edg-1 receptor |
| 04/20/2005 | EP1523555A2 Transgenic animal models of hrv with humani icam-1 sequences |
| 04/20/2005 | EP1523554A2 Method of utilizing the 5' end of transcribed nucleic acid regions for cloning and analysis |
| 04/20/2005 | EP1523553A2 Multiply-substituted protease variants |
| 04/20/2005 | EP1523548A2 Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same |
| 04/20/2005 | EP1523497A2 HSP70 FROM i ARTHROBACTER /i |
| 04/20/2005 | EP1523496A2 Recombinant production of mixtures of antibodies |
| 04/20/2005 | EP1523491A2 Maize clavata3-like polynucleotide sequences and methods of use |
| 04/20/2005 | EP1523333A2 Use of vaccinia virus deleted for the e3l gene as a vaccine vector |
| 04/20/2005 | EP1523323A2 Reagents and methods for smooth muscle therapies |
| 04/20/2005 | EP1523322A2 Novel proteins and nucleic acids encoding same |